Who We Are
• Venture Investment Bank for Early
Stage Technology Companies
• We Invest Through:
– Angel & Institutional Investor Members
– Capital Managed Internally
• NASD\Broker Dealer
The Fact is……
VCs Don’t Invest in Early Stage
Companies
Angels Do!
Early Stage
Seed
‘A’ Round ‘B+’ Rounds
Mezzanine
IPO/Exit
$10 - $30M
$40M+
Capital Chasm
$200k
$.5 – $5M
$10M+
Ten Highly Effective Habits of
Successful Angel Investing
1.
Get out 20 Envelopes
Ten Highly Effective Habits of
Successful Angel Investing
2.
Be Quick but don’t Hurry
Ten Highly Effective Habits of
Successful Angel Investing
3.
Invest in Deals you Understand
Ten Highly Effective Habits of
Successful Angel Investing
4.
Don’t try to change the Company
Ten Highly Effective Habits of
Successful Angel Investing
5.
Do your own Competitive
Analysis Research
Ten Highly Effective Habits of
Successful Angel Investing
6.
Get to KNOW the Customer
Ten Highly Effective Habits of
Successful Angel Investing
7.
Really get to KNOW the Team
Ten Highly Effective Habits of
Successful Angel Investing
8.
Never, ever Fall in Love
Ten Highly Effective Habits of
Successful Angel Investing
9.
Know the Intellectual Property
Ten Highly Effective Habits of
Successful Angel Investing
10. Know who you pass the Baton
to – before you invest
Our Value Proposition
is
Superior Deal Selection
&
Superior Deal Support
Deal Selection Process
•
•
•
•
Initial Screening by Angel Capital Staff
Qualified Deals go to Expert Angel
Members for Analysis
Engage VCs in Due Diligence Review
Engage Relevant Strategic Investors
Deal Selection Criteria
• Angel Investors with Deep Relevant
Industry Experience Willing to:
– Invest
– Serve as Advisors
• VCs Willing to Fund Later Rounds
Based on Certain Milestones
• Defensible IP
Deal Support
•
Introduce:
–
–
–
–
•
•
Expert Angels Who Invest and Join Board
Industry Board Members
Strategic Relationships
VCs with Relevant Expertise
Valuation and Deal Structure
Ongoing Corporate Finance Services
• Disruptive Technology in Intelligent Storage
Networks
• 12 patents filed, more to come
• Market projected to grow 900% by 2003 to $6.7B
• Experienced management team has built two
successful companies
• Elite industry board
• Key industry relationships in place
BioRight International, Inc.
Breakthrough Nonprescription Cold
& Allergy Medicines
•Launched 11/00 - Sales Exceeding $1.3 Million
•Distribution in Over 22,000 Retail Pharmacies –
Walgreens, Rite-Aid, Eckerds, Safeway, Osco, Longs
•Pipeline for New Product Introductions
•Revenue Growth to Over $100 Million Within 5 Years
•Management Combines Medical Expertise With 25
Year Track Record of Retail Product Introductions
• Multifocal Contact Lens With Strong Patents and
High Consumer Demand
• Clinical Data Consistently Outperforms Any Lens
on the Market (Including J&J Acuvue)
• FDA Approval Received for:
– Custom (Lathed Lens) Launched in US and Canada
– Cast Molded Lens (Disposable & Mass Produced)
• CE Mark Received for Astigmatic Intraocular Lens
Contact Information
• Mike Pogue - President
– (415) 289-4618
– mpogue@angelcapitalnetwork.com